HOPENCT06992427
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 212 → 216 locations
- Notable Eligibility criteria expanded, about 24 words
- Trial sites expanded: 200 → 212 locations
- Secondary endpoints: details revised at 2 of 2 entries
- Study description revised
- Minor Trial sites expanded: 187 → 200 locationsv10
- Minor Trial sites expanded: 154 → 187 locationsv9
- Minor Study sites: 150 to 154v8
Show 6 earlier versionsHide 6 earlier versions
- Minor Study sites: 146 to 150v7
- Minor Study sites: 111 to 146v6
- Minor Study sites: 95 to 111v5
- Minor Study sites: 72 to 95v4
- Minor Study sites: 6 to 72v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 6
- Start date changed from estimate of May 31, 2025 to Jun 5, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
Starting by radiation treatment 8, patients receive placebo PO QD on day 1, BID on day 2, then TID starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with placebo continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive placebo TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study.
Starting by radiation treatment 8, patients receive gabapentin PO QD on day 1, BID on day 2, then TID starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with gabapentin continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive gabapentin TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study.
Drugs: Gabapentin, Placebo, Chemotheraphy, Analgesic Agent
Radiation: Radiation Therapy
Procedures: Biospecimen Collection
Other: Survey Administration
Sites
216 sites in 1 country